Liposcience Announces Agreement With ARUP Clinical Laboratories For Placement Of Vantera® Clinical Analyzer

Agreement Supports Strategy to Decentralize NMR Technology and Enhance Access to the NMR LipoProfile® Test for Cardiovascular Disease Management

RALEIGH, N.C. – July 29, 2013 –LipoScience, Inc., (NASDAQ: LPDX) a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced an agreement to place the Vantera® Clinical Analyzer within ARUP Laboratories’ facilities. The agreement will make NMR lipoprotein testing on the Vantera Clinical Analyzer accessible to customers of ARUP Laboratories later this year.

The Vantera Clinical Analyzer can identify and quantify concentrations of lipoproteins using NMR spectroscopy and proprietary signal processing algorithms. Such analysis provides physicians and patients with a detailed assessment of cardiovascular disease (CVD) risk from a single blood test that measures the concentration of low-density lipoprotein particles (LDL-P) and other lipoprotein information within a patient’s blood sample.

LDL-P is the first FDA-cleared assay on the Vantera Clinical Analyzer and a key component of LipoScience’s NMR LipoProfile® test. To date, over 10 million NMR LipoProfile tests have been ordered to aid in CVD risk management. Adoption and decentralization of the Vantera Clinical Analyzer into clinical laboratories will ultimately provide widespread access to the NMR LipoProfile test, reduce sample processing turnaround time and provide value to physicians focused on delivering quality patient care and personalized management of cardiovascular disease.

“Historically, LipoScience has processed all samples for the NMR LipoProfile test. We are excited to offer NMR lipoprotein testing and other NMR-based assays as the Vantera menu expands, directly through our laboratory,” said Dr. Jerry Hussong, chief medical officer at ARUP. “Providing information on LDL-P, which has been shown to correlate with cardiovascular disease risk, supports our efforts to streamline patient management through timely provision of personalized information.”

“Having ARUP Laboratories place the Vantera Clinical Analyzer and offer the NMR LipoProfile test is a significant milestone as we drive toward regional access and widespread adoption of the test,” said Peter Riefenhauser, vice president of marketing at LipoScience. “This placement is consistent with our vision of NMR diagnostics becoming a clinical standard of care for measuring lipoproteins and other small-molecule metabolites to advance patient care.”

About LipoScience, Inc.

LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The company’s first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low-density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 10 million NMR LipoProfile tests have been ordered. LipoScience’s automated clinical analyzer, Vantera®, has been cleared by the U.S. Food and Drug Administration (FDA). It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk-away automation. The Vantera Clinical Analyzer will be placed with national and regional clinical laboratories.

LipoScience is driving NMR diagnostics toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit and

About ARUP Laboratories

Founded in 1984, ARUP Laboratories is a leading national reference laboratory and a nonprofit enterprise of the University of Utah and its Department of Pathology. ARUP offers more than 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. ARUP serves clients across the United States, including many of the nation’s top university teaching hospitals and children’s hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and other government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology®.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include expectations regarding the capabilities and availability of the Vantera Clinical Analyzer and the Company's ability to increase and sustain demand for its NMR LipoProfile test, as well as the Company's plans for future diagnostic tests on the Vantera platform. The achievement or success of the matters covered by such forward-looking statements involve risks, uncertainties and assumptions, and if any such risks or uncertainties materialize or if any of the assumptions prove incorrect, the Company's results could differ materially from the results expressed or implied by the forward-looking statements it makes. These risks and uncertainties include, but are not limited to, risks associated with the receptiveness of third-party laboratories with respect to the placement of Vantera Clinical Analyzers at their facilities, the Company's ability to expand its sales and marketing capabilities in order to increase demand for the NMR LipoProfile test and any future tests that it may develop, the Company's ability to compete with other diagnostic testing methods that may be more widely accepted and the Company's ability to secure regulatory clearance by the FDA of the non-cleared portions of the NMR LipoProfile test. Further information on these and other factors that could affect the Company's results is included in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and other filings the Company makes with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations page of the Company's website. The statements made in this release are based on information available to LipoScience as of the date of this release, and the Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.